{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-04T00:40:43.153057+00:00","company":{"ticker":"SLDB","cik":1707502,"company_name":"Solid Biosciences Inc."},"pagination":{"limit":100,"returned":3,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"material_agreement","fact_key":"2e58e3a06a2fa9815a1aafa41ab9d438a166023c","cik":1707502,"ticker":"SLDB","company_name":"Solid Biosciences Inc.","filed_at":"2026-03-06T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"certain institutional accredited investors","effective_date":"2026-03-06","item_codes_triggered":["1.01"],"value_text":"approximately $240.0 million"},"claim":"Solid Biosciences Inc. entered into Securities Purchase Agreement with certain institutional accredited investors valued at approximately $240.0 million (effective 2026-03-06).","evidence_excerpt":"On March 6, 2026, Solid Biosciences Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain institutional accredited investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 14,973,257 shares of the Company’s common stock, par value $0.001 per share (the “ Shares ”), at a price of $5.61 per share, and, to investors who so choose in lieu of Shares, pre-funded warrants to purchase 27,807,482 shares of the Company’s common stock (the “ Pre-Funded Warrants ”), at a price of $5.609 per Pre-Funded Warrant (the “ Private Placement ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-096709","anchor_url":"https://secwatch.observer/filing/0001193125-26-096709#claim-2e58e3a06a2fa9815a1aafa41ab9d438a166023c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312526096709/0001193125-26-096709-index.htm"},{"fact_type":"executive_change","fact_key":"c159b08908","cik":1707502,"ticker":"SLDB","company_name":"Solid Biosciences Inc.","filed_at":"2024-06-11T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-06-11","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Rajeev Shah resigned as Director at Solid Biosciences Inc..","evidence_excerpt":"Rajeev Shah notified the Company of his decision to resign as a member of the Board, effective as of June 11, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-159143","anchor_url":"https://secwatch.observer/filing/0001193125-24-159143#claim-c159b08908","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312524159143/0001193125-24-159143-index.htm"},{"fact_type":"executive_change","fact_key":"a1a3ed58b3","cik":1707502,"ticker":"SLDB","company_name":"Solid Biosciences Inc.","filed_at":"2024-06-11T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-06-11","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Adam Koppel resigned as Director at Solid Biosciences Inc..","evidence_excerpt":"Adam Koppel notified Solid Biosciences Inc. (the “Company”) of his decision to resign as a member of the Company’s Board of Directors (the “Board”), effective as of June 11, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-159143","anchor_url":"https://secwatch.observer/filing/0001193125-24-159143#claim-a1a3ed58b3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312524159143/0001193125-24-159143-index.htm"}]}